Twenty-Two Diseases Prioritized for the Africa CDC Framework for Action
| Archetype | Disease | Vaccine Exists? | African Doses Volume by 2040, million | Disability-Adjusted Life Years 2040, million |
|---|---|---|---|---|
| Legacy: diseases with high coverage vaccines, primarily produced by Indian players at high volumes with low unit prices. | Hepatitis B, diphtheria, tetanus, whooping cough | Yes | ∼370 | 6 |
| TB | Yes | ∼140 | 12 | |
| Measles | Yes | ∼240 | 2 | |
| Yellow fever | Yes | ∼50 | <1 | |
| Cholera | Yes | ∼30 | 1 | |
| Typhoid | Yes | ∼20 | 1 | |
| Meningococcusa | Yes | ∼60 | 5 | |
| Expanding: diseases that do not yet have commoditized vaccines, where vaccines are sold at relatively higher prices with some products still in development and not yet licensed. | Human papillomavirus | Yes | ∼30 | 4 |
| Pneumococcus | Yes | ∼140 | 13 | |
| Rotavirus | Yes | ∼120 | 9 | |
| COVID-19 | Yes | ∼710 | TBD | |
| Malaria | Yes | ∼120 | 20 | |
| HIV | No | ∼110 | 10 | |
| Outbreak: diseases that are characterized by having emerging vaccines with unpredictable demand driven by outbreaks, often with higher prices due to lower scale and urgent need. | Ebola | Yes | ∼1 | 9 |
| Influenzab | Yes | ∼10 | 1 | |
| Chikungunya | No | ∼1 | <1 | |
| Rift Valley fever | No | ∼1 | <1 | |
| Lassa fever | No | ∼1 | <1 | |
| Disease Xc | No | N/A | N/A | |
| Total | 2,200 |
Abbreviations: Africa CDC, Africa Centres for Disease Control and Prevention; N/A, not applicable; TBD, to be determined.
↵a Including key meningococcus serogroups found in Africa (A, C, W, and X).
↵b In this context, outbreak influenza.
↵c Disease X refers to a hypothetical, unknown pathogen that could emerge and result in an epidemic.